Hyperuricemia is characterized by elevated serum uric (SUA) levels beyond 6.8mg/dl and is a major cause of gout. Clinically, the high uric acid levels are managed using oral xanthine oxidase inhibitors such as febuxostat; however, its long-term use affects liver functions and cannot be used with the person with compromised liver functions. Thus, searching for an alternate xanthine oxidase inhibitor devoid of side effects on the liver is of current interest. Several classes of XO inhibitors have been patented in recent years. Using a docking study, we investigated the binding mode of xanthine oxide inhibitors patented during 2011-2020.The study identified the crucial amino acid residues involved in drug-receptor interactions. The binding side residues and their role in stabilizing the drug-receptor complex is discussed in detail. The information gained from this study will help researchers to design potent and selective xanthine oxidase inhibitors to manage gout and other uric acid-related disorders effectively.

Acrylamide is a yellowish, odorless solid that is water-soluble and is used in a variety of organic solvents and organic chemical compounds. It is used as a precursor or substitute for water-soluble thickeners in a variety of applications. It is very toxic and hence carcinogenic, and it is administered as a watery solution. Aside from exposure to the industry and cigarettes, food appears to be the most common source of human exposure. Cancer has remained the second-leading cause of death, with a global increase in the number of cases. Increasing the cancer burden necessitates the use of cancer preventive methods. Because of the present results of several future investigations, specialists have conducted a new meta-analysis on the usage of acrylamide-related illness incidence in various areas. Authors discovered 32 publications on their own. The researchers conducted a meta-analysis utilizing corrected or spontaneous modeling, based on the heterogeneous method, to assess the overall chance for each cancer site for highest versus  lowest consumption levels, including an increase in nutritional acrylamide by 10 mg/day. Acrylamide has been classified by the International Agency for Research on Cancer as a human category 2A carcinogen, based on evidence of acrylamide carcinogenicity in animals.

No abstract

No abstract